Biography
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of Chicago | M.D. | School of Medicine | 1996 |
Board Certifications
American Board of Radiology
Awards & Honors
Award | Conferred By | Date |
---|---|---|
Commitment to Patient Care Award | UCSF | 2012/2013 |
Lifetime Teaching Award | UCSF | 2012/2013 |
Educator of the Year | UCSF | 2009/2010 |
Clinical Expertise
Brain and Spinal Tumors
CyberKnife Irradiation for Lung and Skull Base
Esophageal Cancer
Intensity-modulated radiation therapy (IMRT)
Sarcoma
Stereotactic Lung Radiotherapy (SBRT)
Non-Small Cell Lung Cancer
Small-Cell Lung Cancer
External-beam Radiation
Bronchioloalveolar Carcinoma (BAC)
Clinical Trials
- Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer (NCT00750269)Related Conditions: Lung Cancer, Non-Small Cell Lung Cancer, Lung Tumor| Start Date: | End Date:
Program Affiliations
Thoracic Oncology Program
Department of Radiation Oncology
Helen Diller FamilyComprehensive Cancer Center
Sarcoma Program
Research Narrative
Dr. Gottschalk is involved in a number of clinical research projects. First, he has studied several methods of image-guided radiotherapy (IGRT), including, ultrasound, electronic portal imagining using gold seed fiducial markers and megavoltage cone-beam CT (MVCBCT). His research is one of the first to evaluate prostate bed motion in patients undergoing radiotherapy after prostatectomy. Dr. Gottschalk has investigated the use of MVCBCT for dose calculation and re-calculation as well as a novel high quality, low dose, imaging beam line. The dose re-calculation can be use for dose guided radiation therapy (DGRT).
Second, using the Radiation Oncology clinical database, Dr. Gottschalk has studied: the effectiveness of intraoperative radiation therapy (IORT) in the management of extremity sarcomas and renal cell carcinoma recurrences, permanent seed brachytherapy and high dose-rate brachytherapy (HDR) for the treatment of prostate cancer both as primary therapy and as salvage after radiation failures.
Third, he has been involved as a co-investigator in three trials: a Phase 2, Single-Center, Open-Label phase I/II study to evaluate safety and efficacy and Safety in patients who have resectable esophageal cancer and are treated with neoadjuvant cisplatin, irinotecan (CPT-11), ZD1839 (IRESSA®), and radiotherapy followed by surgical resection; a phase II study of radiation therapy, paclitaxel poliglumex and carboplatin in stage III non-small cell lung cancer; and a phase I/II open-label dose escalation study of anti-CTLA4 antibody with radiation for metastatic hormone refractory prostate cancer.
Forth, Dr. Gottschalk is involved with several RTOG (Radiation Therapy Oncology Group) studies. These have included several prostate cancer trials that investigate: high-dose vs standard-dose readiation for intermediate-risk prostate cancer; brachytherapy vs external-beam radiation plus brachytherapy for intermediate-risk prostate cancer; and standard fractionation vs hypofractionation for low-risk prostate cancer. Finally, as Director of the CyberKnife Radiosurgery Program Dr. Gottschalk oversees several of the stereotactic body radiosugery (SBRT) trials for lung and prostate cancer. He has a particular interest in the use of CyberKnife SBRT for the treatment of prostate cancer, kidney cancer, and lung cancer.
Research Interests
- Radiation in combination with chemotherapy and targeted agents
- Image-guided and adaptive radiation therapy
- Radiation sensitizers and protectors
Publications
- Management of isolated renal fossa recurrence following radical nephrectomy.| | PubMed
- Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism.| | PubMed
- PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.| | PubMed
- Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.| | PubMed
- High-resolution dental magnetic resonance imaging of inferior alveolar nerve responses to the extraction of third molars.| | PubMed
- The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials.| | PubMed
- eat-2 and eat-18 are required for nicotinic neurotransmission in the Caenorhabditis elegans pharynx.| | PubMed
- Evaluation of ultrasound-based prostate localization for image-guided radiotherapy.| | PubMed
- Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.| | PubMed
- [The prognostic value of quantified MRI at an early stage of Bell's palsy].| | PubMed